Alembic Pharmaceuticals posts Q4 FY25 consolidated PAT at Rs. 156.63 Cr

The company has posted net profit of Rs. 582.01 crores for the Financial Year ended March 31, 2025

Innoxel Lifesciences completes USFDA inspection

This outcome reflects Innoxel Lifesciences' ongoing commitment to maintaining the highest standards of quality, compliance, and regulatory excellence

OneSource Specialty Pharma reports consolidated Q4 FY25 PAT at Rs. 98.50 Cr

The company has posted net loss of Rs. 17.97 crores for the Financial Year ended March 31, 2025

GPT Healthcare commissions new greenfield quaternary care hospital in Raipur

Biocon Biologics secures strong market coverage for Yesintek in US

Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025

RPG Life Sciences posts Q4 FY25 net profit at Rs. 117.35 Cr

RPG Life Sciences has reported total income of Rs. 148.15 crores during the period ended March 31, 2025

AstraZeneca’s Breztri met primary endpoints in KALOS and LOGOS Phase III trials in asthma

Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease

SMS Pharmaceuticals’ Vizag plant receives WHO Geneva prequalification

This significant milestone enhances our global regulatory standing

Alembic receives USFDA final approval for Ticagrelor Tablets, 90 mg and tentative approval for Ticagrelor Tablets, 60 mg

Ticagrelor tablets are indicated for to reduce the risk of cardiovascular death and myocardial infarction,

USFDA inspection at Concord Biotech’s API facility at Dholka

These observations are procedural in nature and none of them are related to data integrity